For the Inventor, By the Inventor

Enter assignee name

Cardiff, United Kingdom

Verona Pharma Plc

USPTO Granted Patents = 18

% Expired Patents = 5.6

CIPO Patents = 1

EPO Patents = 13

Trademarks = 6

Forward Citations = 117

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Peter Lionel Spargo (9 out of 9 patents)

Edward James French (6 out of 6 patents)

Phillip A Haywood (4 out of 4 patents)

4. Michael J A Walker (4 out of 16 patents)

5. Julian Scott Northen (3 out of 36 patents)

6. Mario Cazzola (3 out of 3 patents)

7. Luigino Calzetta (3 out of 4 patents)

8. Katharine Abbott-Banner (2 out of 2 patents)

9. John Hanrahan (2 out of 2 patents)

10. David Thomas (2 out of 2 patents)

11. David Jack (2 out of 4 patents)

12. Alexander W Oxford (2 out of 58 patents)

13. John Mykytiuk (2 out of 6 patents)

14. Kevin Stephen Turner (2 out of 2 patents)

15. Philippe Fernandes (1 out of 11 patents)

18 patents: Sort by Forward Citations

1. 12734139 - Ensifentrine for decreasing the frequency/severity of COPD exacerbations (2026-09-15),

2. 12409180 - Formulation production process (2025-09-09),

3. 12251384 - Particulate composition (2025-03-18),

4. 12194045 - Particulate composition (2025-01-14),

5. 12168011 - Formulation production process (2024-12-17),

6. 11759467 - Treatment (2023-09-19),

7. 11491155 - Salt of a pyrimido[6,1-A]isoquinolin-4-one compound (2022-11-08),

8. 10945950 - Liquid inhalation formulation comprising RPL554 (2021-03-16),

9. 10864213 - Treatment (2020-12-15),

10. 10710998 - Compound and process (2020-07-14),

11. 10471063 - Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist (2019-11-12),

12. 10463665 - Salt of a pyrimido[6,1-A]isoquinolin-4-one compound (2019-11-05),

13. 9956171 - Liquid inhalation formulation comprising RPL554 (2018-05-01),

14. 9717732 - Drug combination (2017-08-01),

15. 9700558 - Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist (2017-07-11),

Verona Pharma Plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases. The company's lead drug candidate is RPL554, a first-in-class inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, intended for the treatment of COPD and cystic fibrosis. Verona Pharma is dedicated to improving the lives of people suffering from respiratory conditions through the development of safe and effective medications.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

18 Patents

#5 in Cardiff

#995 in United Kingdom

#34,146 in the World

Cardiff, United Kingdom

Verona Pharma Plc

Forward Citations = 117

19 inventors:

Peter Lionel Spargo (9 out of 9 patents)

Edward James French (6 out of 6 patents)

Phillip A Haywood (4 out of 4 patents)

4. Michael J A Walker (4 out of 16 patents)

5. Julian Scott Northen (3 out of 36 patents)

Please report any incorrect information to [email protected]

Loading…